Novartis trial suspensions seen as limited financial impact
Citi analysts said Novartis’s decision to suspend several cell-therapy clinical trials after three patient deaths is expected to have limited financial impact, pending further updates.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.